The Escherichia coli BglF protein, an enzyme II of the phosphoenolpyruvate-dependent carbohydrate phosphotransferase system, has several enzymatic activities. In the absence of ␤-glucosides, it phosphorylates BglG, a positive regulator of bgl operon transcription, thus inactivating BglG. In the presence of ␤-glucosides, it activates BglG by dephosphorylating it and, at the same time, transports ␤-glucosides into the cell and phosphorylates them. The Escherichia coli BglF protein (EII bgl ), an enzyme II (EII) of the phosphoenolpyruvate (PEP)-dependent carbohydrate phosphotransferase system (PTS), catalyzes concomitant transport and phosphorylation of ␤-glucosides (11). In addition, BglF regulates bgl operon expression by controlling the activity of the transcriptional regulator BglG. In the absence of ␤-glucosides, BglF phosphorylates BglG, thus inactivating it; in the presence of ␤-glucosides, BglF dephosphorylates BglG, which can then function as a transcriptional antiterminator and enable bgl operon expression (1, 2, 3, 24) . Thus, BglF is the ␤-glucoside phosphotransferase, the BglG kinase, and the phosphorylated BglG (BglG-P) phosphatase. A dimeric form of BglF can catalyze all these activities (7).
The Escherichia coli BglF protein (EII bgl ), an enzyme II (EII) of the phosphoenolpyruvate (PEP)-dependent carbohydrate phosphotransferase system (PTS), catalyzes concomitant transport and phosphorylation of ␤-glucosides (11) . In addition, BglF regulates bgl operon expression by controlling the activity of the transcriptional regulator BglG. In the absence of ␤-glucosides, BglF phosphorylates BglG, thus inactivating it; in the presence of ␤-glucosides, BglF dephosphorylates BglG, which can then function as a transcriptional antiterminator and enable bgl operon expression (1, 2, 3, 24) . Thus, BglF is the ␤-glucoside phosphotransferase, the BglG kinase, and the phosphorylated BglG (BglG-P) phosphatase. A dimeric form of BglF can catalyze all these activities (7) .
Like other EIIs of the PTS, BglF is composed of three domains. IIA bgl possesses the first phosphorylation site, His-547 (site 1), which is phosphorylated by HPr; IIB bgl possesses the second phosphorylation site, Cys-24 (site 2), which accepts the phosphoryl group from IIA bgl and transfers it to ␤-glucosides; and IIC bgl , the membrane-spanning domain, presumably forms the sugar translocation channel and at least part of the sugar-binding site (9, 25) . The order of these domains in BglF is IIBCA bgl (reviewed in references 17 and 20) . BglF uses site 2, Cys-24 on the IIB bgl domain, to phosphorylate the two substrates, ␤-glucosides and BglG (9) , and to dephosphorylate BglG-P (10). A rearranged BglF protein which contains the three domains in the order IICBA bgl (scrambled-BglF) catalyzes BglG phosphorylation but fails to carry out the sugarinduced reactions, i.e., sugar phosphotransfer and BglG-P dephosphorylation (8) . These findings suggest that the structural requirements for the sugar-induced functions differ from those for the noninduced function. The key to BglF stimulation, i.e., the sugar-induced change which switches it from a BglG kinase mode to a BglG-P phosphatase and sugar phosphotransferase mode, is not understood.
To define the domain(s) required for catalysis of the different functions of BglF, we subcloned and expressed the three individual domains, IIA bgl , IIB bgl , and IIC bgl , as well as truncated BglF proteins which lack one domain (IIBC bgl and IICA bgl ). We show that phosphorylated IIB bgl alone can phosphorylate BglG in vitro and negatively regulate its activity as a transcriptional antiterminator in vivo. In contrast, IIBC bgl is required for ␤-glucoside phosphorylation in vitro and for ␤-glucoside utilization in vivo. The same holds true for BglG-P activation by dephosphorylation. These results suggest that the immediate environment of the BglF active site changes upon sugar stimulation. This change induces specific interactions between the active site-containing domain, IIB bgl , and the membrane-bound domain, IIC bgl .
MATERIALS AND METHODS

Strains.
The following E. coli K-12 strains were used. K38 (HfrC trpR thi ϩ ) was obtained from C. Richardson. LM1 contains mutations in the nagE and crr genes, which code for EII nag and IIA glc , respectively (13) . ZSC112⌬G contains a deletion of the ptsG gene, which codes for IICB glc (6) . PPA501 contains a mutation in the bglF gene and carries a bglЈ-lacZ fusion on its chromosome (9) . SG13009 was obtained from Qiagen.
Plasmids. The plasmids that encode the BglF derivatives used in this study are listed in Table 1 . Plasmid pACYC184 was obtained from New England Biolabs. Plasmid pQE-30, which contains a translation start site followed by a sequence coding for six histidines and a multicloning site, and plasmid pREP4, which carries the lacI gene encoding the lac repressor, were obtained from Qiagen. Plasmid pT712, which contains the phage T7 late promoter, and plasmid pGP1-2, which carries the T7 RNA polymerase gene under the control of the cI857 repressor, were obtained from Bethesda Research Laboratories. Plasmid pT7OAC-F carries the entire bglF gene cloned downstream of the T7 promoter in pT712 (1). Plasmid pT7CQ-F1, a derivative of pT7OAC-F, encodes BglF with His-547 mutated to Arg (H547R) (9) . Plasmid pMN5 carries the entire bglF gene cloned in pBR322 (14) . Plasmids pT7CQ-F3, pT7CQ-F4, pT7CQ-F5, pT7CQ-F6, and pT7CQ-F8 are derivatives of pT712 which code for IIB bgl , IIC bgl , IIA bgl , IICA bgl , and IIBC bgl , respectively, from the T7 promoter (7). Additional plasmids were constructed as described below.
pACQ 32 P]ATP as described before (1) . Purified enzyme I (EI) and HPr were obtained from J. Reizer. Maltose binding protein (MBP)-BglG was purified as described previously (9) . Ni-nitrilotriacetic acid (NTA) resin was obtained from Qiagen.
Molecular cloning and ␤-galactosidase assay. All manipulations with recombinant DNA were carried out by standard procedures (21) . Assays for ␤-galactosidase activity were carried out as described by Miller (16) . Cells were grown in minimal medium supplied with 0.4% succinate as a carbon source.
[ 35 S]methionine labeling of BglF and its derivatives. Cells of strain K38, containing plasmid pGP1-2 and one of the plasmids carrying the bglF gene or its derivatives under the control of the phage T7 promoter (pT7OAC-F, pT7CQ-F3, pT7CQ-F4, pT7CQ-F6, or pT7CQ-F8), were induced and labeled with [
35 S]methionine in the presence of rifampin (Sigma) as described previously (26) . To study the stability of plasmid-encoded BglF derivatives, unlabeled methionine was added to a final concentration of 0.5 mg/ml to the growth medium (chase) following 2 min of pulse-labeling with [
35 S]methionine, and aliquots were removed at various times for autoradiographic analysis.
Preparation of membrane fractions and cell extracts. Membrane fractions enriched for wild-type BglF or one of its derivatives containing the membranebound IIC domain (H547R, IICA bgl , IIBC bgl , or IIC bgl ) were prepared as described previously (1) . Cell extract enriched for the soluble IIB bgl polypeptide was prepared as described previously for BglG-enriched extract (1). The proteins were expressed from their respective genes cloned under T7 promoter control in plasmids pT7OAC-F, pT7CQ-F1, pT7CQ-F6, pT7CQ-F8, pT7CQ-F4, and pT7CQ-F3, respectively. Expression of T7 RNA polymerase from compatible pGP1-2 was induced thermally. Strain LM1 was used as a host in most cases. When needed, strain ZSC112⌬G (with a deletion of the ptsG gene) was used as a host for IIBC bgl overproduction from pT7CQ-F8. Membrane fractions lacking BglF were prepared from LM1/pGP1-2/pT712 and ZSC112⌬G/pGP1-2/pT712 and were used in control experiments.
Purification of IIA bgl . Expression and purification of IIA bgl were carried out essentially as recommended by Qiagen with some modifications. One liter of SG13009/pREP4/pQE-F5 culture was grown to an optical density at 600 nm of 0.5 in Luria broth containing 200 g of ampicillin and 30 g of kanamycin per ml at 30°C. Isopropyl-␤-D-thiogalactopyranoside (IPTG) was added to a final concentration of 0.1 mM, and growth was continued for 5 h. Cells were harvested by centrifugation at 4,000 ϫ g for 20 min in the cold. The pelleted cells were resuspended in buffer S (50 mM sodium phosphate [pH 7.8], 300 mM NaCl, 0.2 mM phenylmethylsulfonyl fluoride) supplemented with 5 g of DNase and 20 g of RNase per ml and were broken by passing the suspension twice through a French pressure cell at 12,000 lb/in 2 . Unbroken cells were removed by centrifugation at 10,000 ϫ g for 20 min in the cold. The supernatant was mixed gently at 4°C for 16 h with 2 ml of a 50% slurry of Ni-NTA resin preequilibrated in buffer S. The resin was then packed in a column. The column was washed once with buffer S, once with buffer S containing 40 mM imidazole and 10% (vol/vol) glycerol, and once with buffer S containing 250 mM imidazole. Fractions collected during the last wash were analyzed on tricine-sodium dodecyl sulfate (SDS)-polyacrylamide gels, and those containing histidine-tagged IIA bgl were dialyzed against buffer S to remove the imidazole. The protein concentration was determined by the Bradford assay with a kit purchased from Bio-Rad Laboratories.
In vitro phosphorylation. In vitro phosphorylation experiments were carried out essentially as described by Chen et al. (9) . Briefly, membranes with a final protein concentration of 0.9 mg/ml were labeled by incubation at 30°C in a mixture containing 10 g of EI per ml, 40 g of HPr per ml, 10 M [ 32 P]PEP, and PLB buffer (50 mM Na 2 HPO 4 [pH 7.4], 0.5 mM MgCl 2 , 1 mM NaF, 2 mM dithiothreitol). When indicated, cell extracts enriched for IIB bgl and/or purified histidine-tagged IIA bgl were added at final protein concentrations of 0.8 mg/ml and 72 g/ml, respectively. After incubation for 10 min, reactions were either terminated by the addition of electrophoresis sample buffer or further incubated as described below. To study dephosphorylation by ␤-glucosides, salicin was added to a final concentration of 0.2%, and incubation was continued at 30°C for 5 min. To study BglG phosphorylation, purified MBP-BglG in PLB buffer was added to a final concentration of 10 M, and incubation was continued at 30°C for 15 min.
Electrophoresis and autoradiography. Electrophoresis of proteins was carried out on SDS-polyacrylamide gels (12) or on tricine-SDS-polyacrylamide gels (23) . Samples were fractionated next to prestained low-or mid-range-molecularweight markers (Amersham). After electrophoresis, gels were stained with Coomassie blue or directly dried and exposed to Kodak XAR-5 X-ray film at Ϫ70°C. . We then examined the ability of the different polypeptides (i) to be phosphorylated in vitro in the presence of PEP and the general PTS proteins enzyme I (EI) and HPr; (ii) once phosphorylated, to transfer the phosphoryl group to ␤-glucosides and to BglG in vitro; and (iii) to mediate ␤-glucoside utilization and modulate BglG activity in vivo.
RESULTS
To define the domains required for the different functions of
The stability of the different plasmid-encoded polypeptides was assayed with pulse-chase experiments. The proteins were labeled with [
35 S]methionine and chased with unlabeled methionine. Samples removed at different times were analyzed by SDS-polyacrylamide gel electrophoresis. The results (Fig. 1) demonstrate that IIB bgl , IIC bgl , IICA bgl , and IIBC bgl expressed from the heat-inducible T7 promoter are very stable, like wild-type BglF, although they are produced at variable levels.
Due to the low level of IIA bgl produced under the control of the T7 promoter, we engineered histidine-tagged IIA bgl expressed from an IPTG-inducible promoter (see Materials and Methods). The His-tagged IIA bgl polypeptide was purified almost to homogeneity by affinity chromatography (Fig. 2A) . The ability of His-tagged IIA bgl to accept a phosphoryl group from HPr and to deliver it to site 2 of BglF was tested in vitro as follows. Purified His-tagged IIA bgl was incubated with [ 32 P] PEP, purified EI and HPr, and membranes of strain LM1 (with deletions of the crr and nagE genes) enriched for a BglF mutant protein which lacks phosphorylation site 1 (H547R bgl , which can then deliver it to ␤-glucosides or to BglG (9) . It has also been demonstrated that the dephosphorylation of BglF in the presence of ␤-glucosides in vitro is a good indication of the ability of BglF to transfer the phosphoryl group to the sugar (1). We therefore tested the ability of different combinations of BglF domains to be phosphorylated in vitro and then to be dephosphorylated by the ␤-glucoside salicin.
To test IIBC bgl phosphorylation and dephosphorylation, we produced the protein in strain ZSC112⌬G, which has a deletion of the ptsG gene. This strain does not contain IICB glc , which is present in membrane preparations of E. coli strains, such as LM1, in significant amounts (9) Fig. 3B . IIB bgl was phosphorylated in all cases (Fig. 3B, lanes 1, 3, and 5) ; i.e., it could accept the phosphoryl group from His-tagged IIA bgl or from IICA bgl . However, phosphorylated IIB bgl was not dephosphorylated by salicin in any of these cases (Fig. 3A, lanes 2, 4, and 6 (Fig. 4, lane 6 ). IIC bgl was dispensable for phosphoryl transfer from phosphorylated IIA bgl to IIB bgl and from phosphorylated IIB bgl to MBP-BglG (Fig. 4, lane 4) . IIA bgl was required for these phosphorylation reactions (Fig. 4, lane 8 membranes that lacked BglF and that were prelabeled in the in vitro phosphorylation reaction (Fig. 4, lane 1) . This result is in agreement with our previous observation that phosphorylated EI and HPr cannot phosphorylate BglG (9) . Based on the results presented here, it can be concluded that IIB bgl alone can accept the phosphoryl group from phosphorylated IIA bgl and transfer it to BglG. IIC bgl is not involved in these phosphotransfer reactions. However, phosphorylated IIB bgl separated from IIC bgl is incapable of delivering its phosphoryl group to ␤-glucosides. In contrast, phosphorylated IIBC bgl can catalyze ␤-glucoside phosphorylation. IIB bgl can negatively regulate BglG antitermination activity, whereas IIBC bgl is required for ␤-glucoside utilization and for the relief of BglG inhibition in vivo. To substantiate our in vitro results by in vivo studies, we analyzed the ability of different combinations of BglF domains to transfer ␤-glucosides into the cell while phosphorylating them and to negatively regulate BglG activity as a transcriptional antiterminator.
We first tested whether plasmids which encode the individual BglF domains or domain pairs can complement a bglF mutant strain. To this end, the different truncated BglF proteins or certain combinations encoded by compatible plasmids were produced in the bglF strain PPA501. This strain produces IIA glc and EII nag , which can substitute for IIA bgl (9, 25) . Complementation is indicated by growth on minimal arbutin plates and by the formation of red colonies on MacConkey arbutin plates. Utilization of the ␤-glucoside arbutin depends on the ability of the plasmid-encoded BglF derivatives to phosphorylate and transport this sugar, which is then cleaved by the product of the unlinked locus bglA. Utilization of the ␤-glucoside salicin is prohibited in this strain due to the polarity of the mutation in bglF on the cotranscribed bglB gene, whose product preferentially cleaves phosphosalicin (14) . The results are presented in Table 2 . Only IIBC bgl behaved like wild-type BglF and complemented the bglF mutant strain. These in vivo observations demonstrated that separated IIB bgl and IIC bgl cannot complement each other to enable ␤-glucoside transport and phosphorylation. IIBC bgl is required for ␤-glucoside utilization in vivo, as predicted from in vitro data. The failure of the unjoined domains to complement the bglF mutant strain cannot be explained by insufficient levels of the separated domains. Although the effective relative concentrations of the IIB and IIC domains are higher in the linked polypeptide than when they are not covalently joined, the individual domains in this experiment were expressed from multicopy plasmids. In addition, soluble IIB bgl is expressed much more efficiently than IIBC bgl and BglF ( Fig. 1 ; note that IIB contains only three methionines).
The ability of BglF to inactivate the transcriptional antiterminator BglG in the absence of ␤-glucosides stems from its ability to phosphorylate BglG. The relief of BglG inhibition upon ␤-glucoside addition is due to the dephosphorylation of BglG by sugar-stimulated BglF (1). Therefore, to examine the ability of individual BglF domains, domain pairs, and combinations of domains to phosphorylate and dephosphorylate BglG in vivo, we tested their ability to regulate the activity of BglG as a transcriptional antiterminator. To this end, we made use of strain PPA501, which carries a chromosomal fusion of the bgl promoter and transcriptional terminator to lacZ and which lacks a functional bglF gene. BglG is not negatively regulated by phosphorylation in this strain, and high ␤-galactosidase activity is measured whether or not ␤-glucosides are added to the growth medium (Table 2, line 9). The expression of plasmid-encoded wild-type BglF in strain MA200-1 renders lacZ expression inducible; in the absence of ␤-glucosides, the lacZ gene is not transcribed because BglG is inactivated by phosphorylation; upon the addition of ␤-glucosides, BglF dephosphorylates BglG, allowing it to block transcription termination, and the lacZ gene is expressed ( 
DISCUSSION
The ability of the same active site on BglF to phosphorylate ␤-glucosides and to reversibly phosphorylate BglG prompted us to investigate the structural basis for sugar-controlled differential phosphorylation. Dimerization of BglF could not explain the ␤-glucoside-induced switch in BglF activity, since ␤-glucoside does not affect the BglF dimeric state (7) . In addition, both the sugar-induced and noninduced functions could be catalyzed by BglF dimers, which seem to form spontaneously (7) .
The requirements for ␤-glucoside phosphorylation and for BglG dephosphorylation, both stimulated by the sugar, are expected to be similar and to differ from the requirements for BglG phosphorylation, which occurs in the absence of the sugar. In light of our finding that only the sugar-stimulated activities are sensitive to changing the domain order within BglF (8), we speculated that the domains required for the sugar-stimulated functions might differ from those required for the nonstimulated functions. Of course, the IIB domain, which contains the active site, is expected to be required for all functions. We therefore attempted to define the domains which are required for the different functions by assaying the catalytic activities of individual domains or combination of domains, either covalently linked or produced in trans. Our results (summarized in Table 3 ) showed that intact IIBC bgl is critical for the ability to implement ␤-glucoside phosphorylation and BglG dephosphorylation, whereas BglG phosphorylation can be catalyzed by IIB bgl alone. IIC bgl could not rescue IIB bgl and enable it to catalyze the sugar-stimulated functions, unless it was linked to it, i.e., IIBC bgl . Nonetheless, the domain requirements for the nonstimulated function are quite loose; i.e., the domain which contains the active site, IIB bgl , is sufficient. Phosphotransfer from IIA bgl to IIB bgl is the same in the presence and absence of IIC bgl , suggesting that the activity of IIB bgl as a phosphoryl acceptor is not affected by IIC bgl . These results agree with our previous observation that the order of the domains in BglF (BCA) is critical for ␤-glucoside phosphorylation and BglG dephosphorylation, whereas BglG phosphorylation can be catalyzed by a scrambled-BglF derivative with the domain order CBA (8) . One possible explanation for our previously and currently reported results is that ␤-glucosides induce an interaction between the IIB bgl and IIC bgl domains. Such an interaction could induce a conformational change in BglF and might be the key to the sugarinduced signal transduction pathway that leads to the expression of the bgl operon. In fact, the catalysis of alternative functions due to different interactions between protein domains might be a general theme in the stimulation and/or regulation of diverse functions which are dictated by environmental or cellular conditions. Another possible explanation for our results is suggested by the reversible nature of the BglG phosphorylation reaction (10) . The sugar substrate, by dephosphorylating BglF-P, shifts the equilibrium and leads to dephosphorylation of BglG-P. The role of the IIC domain in this process might be to present the sugar substrate to the phosphorylated IIB domain. The apparent requirement for a covalent connection between the two domains might reflect a requirement that they be in proximity and properly oriented for sugar phosphorylation to occur efficiently. The two explanations are not mutually exclusive. It is possible that a sugarinduced conformation of BglF orients IIC and IIB properly for sugar phosphorylation and BglG dephosphorylation. (18) , and IIA glc complemented a BglF mutant lacking phosphorylation site 1 (9, 25) . Separation of the B domain of the mannitol permease or of the glucose permease from the respective C domain had a more drastic effect, yet catalytic activity was retained to some extent upon their coexpression (6, 19, 27) . Moreover, a circularly permuted derivative of the E. coli glucose permease in which the order of the domains is BC rather than CB, as in the wild-type protein, has activity comparable to that of the wild-type protein (15) . Nevertheless, a mixture of IIA mtl , IIB mtl , and IIC mtl showed 4% the activity of the mannitol permease, which contains all three domains (19) . Similarly, a mixture of IIA glc , IIB glc , and IIC glc showed 2% sugar phosphorylation activity (6) . A fusion protein which incorporates all proteins and protein domains of the glucosespecific PTS into a single polypeptide chain with the domain order IIC glc -IIB glc -IIA glc -HPr-EI increased phosphotransfer activity over that of an equimolar mixture of the isolated subunits. Therefore, the linking of functional domains confers certain advantages to a specific PTS permease by rendering it more efficient (15). We do not have enough evidence yet to decide whether sensitivity to domain splitting and splicing is a characteristic of permeases which recognize similar sugars, of permeases which have more than one function, or of permeases which are related, due to a different, yet unknown, reason. 
a Ability to phosphorylate ␤-glucosides in vitro (Fig. 3) and/or to complement bglF mutant strains ( Table 2) .
b Ability to phosphorylate BglG in vitro (Fig. 4) and/or to negatively regulate BglG activity in vivo ( Table 2 , ␤-galactosidase activity without salicin).
c Ability to restore BglG activity in vivo in the presence of ␤-glucosides ( Table  2 , ␤-galactosidase activity with salicin).
